Cannabis tolerance: how does tolerance to cannabinoids develop?

21/05/2025
Man pondering cannabinoids tolerance at home

Cannabis tolerance develops when regular THC use makes the brain's CB1 receptors less available and less responsive, so the same amount has a weaker effect. Human studies show it is strongest for effects on thinking and memory, and only partial for the high and the heart rate. In daily users, CB1 receptor levels returned to normal after about four weeks without cannabis.

Key facts

Main cause
Repeated THC exposure reduces CB1 receptor numbers (downregulation) and their signalling
Strongest tolerance
Cognitive effects; some studies found no acute effect in regular users
Partial tolerance
The high, psychosis-like effects and heart-rate effects
Recovery
CB1 receptor density back to normal after about 4 weeks of abstinence in one PET study
Who is most affected
People who use high doses often, over a long time

Prefer watching? This video covers the main points.

What is cannabis tolerance?

Tolerance means a substance has less effect after repeated use. With cannabis, the substance in question is mainly THC, the cannabinoid that causes the high. A systematic review of human studies found that regular users generally show smaller acute effects from THC than occasional users, and that effects shrink with repeated doses (Colizzi and Bhattacharyya, 2018).

Tolerance is not the same for every effect. The review found the most tolerance for effects on cognition, sometimes complete. The high, psychosis-like effects and the effect on heart rate were blunted only partly.

Cannabis leaves, illustrating cannabis tolerance

How does cannabis tolerance develop in the brain?

THC acts on CB1 receptors, part of the endocannabinoid system. With frequent exposure, the brain reduces the number of these receptors. A PET imaging study found fewer CB1 receptors in the cortex of daily cannabis smokers, and the reduction was larger the more years they had smoked (Hirvonen et al., 2012).

The reward system changes too. In a randomised, placebo-controlled study, cannabis changed brain connectivity and glutamate levels in occasional users and impaired their attention. The same dose produced none of these changes in chronic users (Mason et al., 2021).

Illustration of the science behind cannabis tolerance

Pharmacological vs behavioural tolerance: what is the difference?

Researchers describe two models. In the pharmacodynamic model, the brain itself adapts, as described above. In the behavioural model, users learn to compensate for impairment by effort. A 2020 review found good evidence for the first model and weak evidence for the second: learned control covers only a few functions, and only to a limited degree (Ramaekers et al., 2020).

Two models of cannabis tolerance
Feature Pharmacodynamic tolerance Behavioural tolerance
What changes CB1 receptors and reward circuitry in the brain The user's learned compensation
Evidence Brain imaging and controlled trials Relatively weak
Reach Several effects, cognition most of all Limited control over a few functions
Reverses with abstinence Yes; CB1 density normalised in about 4 weeks in one study Not studied in the same way

Sources for the table: Ramaekers et al., 2020; Hirvonen et al., 2012; Mason et al., 2021.

Daily cannabis use, a factor in cannabis tolerance development

Who develops tolerance fastest?

According to the 2020 review, tolerance is most likely in people who use high doses continuously, at a high pace, over a long period. The review also notes how little is known about the exact frequency, dose and duration needed to build or lose tolerance (Ramaekers et al., 2020).

Comparing cannabis tolerance with other substances

Does a tolerance break work?

The receptor changes do reverse. In the PET study, daily smokers stayed on a secure research ward without cannabis, and their cortical CB1 receptor density returned to normal levels after about four weeks (Hirvonen et al., 2012). Whether that restores every effect to its earlier level has not been measured in the same detail.

Outdoor hemp crop

Is tolerance the same as dependence?

No. Tolerance means a weaker effect from the same amount. Dependence means finding it hard to stop and having withdrawal symptoms without the drug. The two can go together: the authors of the PET study describe CB1 downregulation as a brain adaptation that may promote cannabis dependence (Hirvonen et al., 2012). If you are worried about your cannabis use, talk to your GP.

The research above is about THC and cannabis. CBD acts differently: in cell studies it does not switch on the CB1 receptor but changes how it responds to other compounds (Laprairie et al., 2015), and it does not cause a high. Read Is CBD addictive? and CBD vs THC for the difference.

Cannabis plant in a field

Frequently asked questions

How does cannabis tolerance develop?

Frequent THC use reduces the number of CB1 receptors in parts of the brain and makes the reward system less responsive. The same amount of THC then has less effect, especially on thinking and memory.

How long does it take for cannabis tolerance to go away?

In a PET study of daily cannabis smokers, CB1 receptor density in the cortex returned to normal after about four weeks without cannabis. How fast each effect returns has not been studied in the same detail.

Do you become tolerant to all effects of cannabis?

No. Human studies show the strongest tolerance to effects on cognition. Tolerance to the high, psychosis-like effects and the effect on heart rate is only partial.

Is tolerance the same as addiction?

No. Tolerance is a weaker response to the same amount. Dependence involves difficulty stopping and withdrawal. Brain changes behind tolerance may contribute to dependence, so the two can occur together.

Can you build a tolerance to CBD?

The tolerance studies summarised here looked at THC and cannabis, not CBD on its own. In cell studies, CBD does not switch on CB1 receptors the way THC does, and it does not cause a high.

This article summarises published research. It is not medical advice. Formula Swiss CBD oils are sold as cosmetics for use on the skin. They are not food supplements or medicines and are not intended to diagnose, treat, cure or prevent any disease.

Last reviewed:

Sources

  1. Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev 2018;93:1–25. doi:10.1016/j.neubiorev.2018.07.014
  2. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17(6):642–649. doi:10.1038/mp.2011.82
  3. Mason NL, Theunissen EL, Hutten NRPW, et al. Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addict Biol 2021;26(1):e12870. doi:10.1111/adb.12870
  4. Ramaekers JG, Mason NL, Theunissen EL. Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance. Eur Neuropsychopharmacol 2020;36:191–205. doi:10.1016/j.euroneuro.2020.01.006
  5. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015;172(20):4790–4805. doi:10.1111/bph.13250
Back to blog

Leave a comment

Please note, comments need to be approved before they are published.

Robin Roy Krigslund-Hansen

Robin Roy Krigslund-Hansen

About the author

Robin Roy Krigslund-Hansen is the co-founder and CEO of Formula Swiss and is responsible for formulation. Since co-founding the company in 2013, he has written about hemp, CBD, and the cannabis industry. His perspective draws on building Formula Swiss, conversations with researchers, and supporting CBD research.

More about Robin Roy Krigslund-Hansen

How we write and check our guides

Related products